Babu Rao Vundinti

Dr. Babu Rao Vundinti

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Gene
Verified
Journal Article
Closed access
DJDolly Joshi
Dolly Joshi
SCS. Chandrakala
S. Chandrakala
SKSeema Korgaonkar
Seema Korgaonkar
KGKanjaksha Ghosh
Kanjaksha Ghosh
BVBabu Rao Vundinti
Babu Rao Vundinti

2 October 2011 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SVShantashri Vaidya
Shantashri Vaidya
KGKanjaksha Ghosh
Kanjaksha Ghosh
BVBabu Rao Vundinti
Babu Rao Vundinti

1 October 2015 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SVShantashri Vaidya
Shantashri Vaidya
KGKanjaksha Ghosh
Kanjaksha Ghosh
CSChandrakala Shanmukhaiah
Chandrakala Shanmukhaiah
BVBabu Rao Vundinti
Babu Rao Vundinti

8 April 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NMNehakumari Maurya
Nehakumari Maurya
PMPurvi Mohanty
Purvi Mohanty
SDSomprakash Dhangar
Somprakash Dhangar
PPPurvi Panchal
Purvi Panchal
FJFarah Jijina
Farah Jijina
BVBabu Rao Vundinti
Babu Rao Vundinti
Myelodysplastic syndromes (MDS) are a group of clonal hematological disease with high risk of progression to AML. Accurate risk stratification is of importance for the proper management of MDS. Genetic lesions (Cytogenetic and Molecular mutations) are known to help in prognosticating the MDS patients. We have studied 152 MDS patients using cytogenetics and next generation sequencing (NGS). These patients were evaluated and as per cytogenetic prognostic group, majority (92.1%) of the patients classified as good (81.6%) and intermediate (10.5%) group. The NGS identified 38 different gene mutations in our cohort. Among 111 MDS patients with mutations, the most frequent mutated genes were SF3B1 (25.2%), SRSF2 (19%) U2AF1 (14.4%) ASXL1 (9.9%) RUNX1 (9.9%) TET2 (9%), TP53 (9%), ATM (6.3%), NRAS (5.4%) and JAK2/3 (5.4%). The survival analysis revealed that the mutations in TP53, JAK2/3, KRAS, NRAS and ASXL1 were significantly (P < 0.05) associated with poor survival of the patients. The univariate cox and multivariate cox analysis of our study suggested that the age, marrow morphology, cytogenetic and gene mutations with IPSS-R should be considered for prognosticating the MDS patients. We have proposed M-IPSS-R which changed the risk stratification i.e. 66.3% patients had decreased risk whereas 33.75% showed increased risk compared to IPSS-R. The survival analysis also showed that the M-IPSS-R were more significant in separating the patients as per their risk than the IPSS-R alone. The change in risk stratification could help in proper strategy for the treatment planning.

1 April 2013 in Gene
Verified
Journal Article
Closed access
PSPallavi Shukla
Pallavi Shukla
ARAnita Rao
Anita Rao
KGKanjaksha Ghosh
Kanjaksha Ghosh
BVBabu Rao Vundinti
Babu Rao Vundinti

17 August 2013 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PSPallavi Shukla
Pallavi Shukla
ASAvani Solanki
Avani Solanki
KGKanjaksha Ghosh
Kanjaksha Ghosh
BVBabu Rao Vundinti
Babu Rao Vundinti